• Eli Lilly (NYSE:LLY) is preparing for the launch of its oral weight loss pill Orforglipron, backing it with large inventory build up and new manufacturing investment ahead of expected approval.
• The company and Scribe Therapeutics reached a key milestone in their collaboration on next generation CRISPR based genetic medicines.
• Lilly also reported a positive Phase 3 trial result for its cancer drug Retevmo in early stage lung cancer.

For you as an investor, these updates highlight how Eli Lilly is focusing on weight loss, oncology, and genetic medicine at the same time. The company is already widely followed for its obesity and diabetes treatments, and Orforglipron aims to extend that presence into oral therapies that could appeal to patients who prefer pills over injections.

The collaboration progress with Scribe Therapeutics and the Phase 3 data for Retevmo point to a pipeline that reaches beyond obesity and diabetes. As approvals, manufacturing ramp up, and additional trial readouts unfold, the mix of products drawing attention to NYSE:LLY could broaden across segments of healthcare.

Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.

Quick Assessment

• ✅ Price vs Analyst Target: At US$1,036.05, Eli Lilly trades about 14% below the US$1,201.63 analyst target.
• ✅ Simply Wall St Valuation: Our model indicates the shares trade around 26.1% below estimated fair value.
• ❌ Recent Momentum: The 30 day return sits at roughly a 0.2% decline, so the price has been soft recently.

There is only one way to know the right time to buy, sell or hold Eli Lilly. Head to Simply Wall St's company report for the latest analysis of Eli Lilly's fair value.

Key Considerations

• 📊 Orforglipron, the Scribe Therapeutics collaboration, and Retevmo all point to a multi pillar pipeline across obesity, oncology, and genetic medicine.
• 📊 Watch how inventory levels, manufacturing capacity, and regulatory decisions for Orforglipron line up with revenue and earnings trends.
• ⚠️ With 2 flagged risks including debt levels and non cash earnings, consider how future R&D and manufacturing spend could affect the balance sheet and reported profit quality.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can check out the community page for Eli Lilly to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.